Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix vaccine in adults ≥50 years with prior herpes zoster
NCT04091451Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2019
- Primary completion
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in herpes zoster (HZ) comparing HZ/su Group with Placebo Group (2 arms). Primary endpoint: Incidence Rate of Confirmed Herpes Zoster Cases. Started Sep 2019; status: completed.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT04091451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091451.